Veracyte Inc 2023 SR
The report highlights Veracyte's commitment to transforming cancer care through molecular diagnostics, focusing on high-priority ESG topics like patient access, corporate governance, and environmental sustainability. In 2022, the company launched the Vera Culture 2.0 initiative to define core values and enhance employee engagement. Veracyte achieved significant gender diversity, with women comprising 59% of the global workforce and 60% of the executive leadership team. The company also aligned its disclosures with SASB standards and is pursuing BREEAM certification for its new facility in Marseille, France.
Company: Veracyte Inc
Sector: Healthcare & social services
Country: United States
Year: 2023
Type: SR
Pages: 52
Back to company
Veracyte Inc
ESG Report
The report highlights Veracyte's commitment to transforming cancer care through molecular diagnostics, focusing on high-priority ESG topics like patient access, corporate governance, and environmental sustainability. In 2022, the company launched the Vera Culture 2.0 initiative to define core values and enhance employee engagement. Veracyte achieved significant gender diversity, with women comprising 59% of the global workforce and 60% of the executive leadership team. The company also aligned its disclosures with SASB standards and is pursuing BREEAM certification for its new facility in Marseille, France.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Jan 1, 2022 - Dec 31, 2022
Fiscal Year
2022
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Employees